References
Key articles
World Health Organization. WHO guidelines for malaria. Oct 2023 [internet publication].Full text
Centers for Disease Control and Prevention. Clinical guidance: malaria diagnosis & treatment in the U.S. Jun 2024 [internet publication].Full text
Reference articles
1. Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005 Mar 10;434(7030):214-7.Full text Abstract
2. Isaacson M. Airport malaria: a review. Bull World Health Organ. 1989;67(6):737-43.Full text Abstract
3. Evans RJ. Nosocomial malaria. Lancet. 1997 Feb 22;349(9051):574. Abstract
4. Moro ML, Romi R, Severini C, et al. Patient-to-patient transmission of nosocomial malaria in Italy. Infect Control Hosp Epidemiol. 2002 Jun;23(6):338-41. Abstract
5. Das D, Bhattacharjee K, Ghintala S, et al. Bilateral cervical lymphadenopathy atypical presentation of malaria - a rare case report. J Clin Diagn Res. 2017 Apr;11(4):OD08-9.Full text Abstract
6. Groger M, Fischer HS, Veletzky L, et al. A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria. Malar J. 2017 Mar 11;16(1):112.Full text Abstract
7. World Health Organization. World malaria report 2023. Nov 2023 [internet publication].Full text
8. Mace KE, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2018. MMWR Surveill Summ. 2022 Sep 2;71(8):1-35.Full text Abstract
9. Mitchell CL, Kennar A, Vasquez Y, et al. Notes from the field: increases in imported malaria cases - three southern U.S. border jurisdictions, 2023. MMWR Morb Mortal Wkly Rep. 2024 May 9;73(18):417-9.Full text Abstract
10. Centers for Disease Control and Prevention. Locally acquired (autochthonous) mosquito-transmitted Plasmodium vivax malaria - Saline County, Arkansas, September 2023. Oct 2024 [internet publication].Full text
11. Centers for Disease Control and Prevention. Morbidity and mortality weekly report (MMWR): outbreak of locally acquired mosquito-transmitted (autochthonous) malaria - Florida and Texas, May-July 2023. Sep 2023 [internet publication].Full text
12. Centers for Disease Control and Prevention. Emergency preparedness and response: important updates on locally acquired malaria cases identified in Florida, Texas, and Maryland. Aug 2023 [internet publication].Full text
13. UK Health Security Agency. Imported malaria in the UK: statistics. Apr 2024 [internet publication].Full text
14. World Health Organization. Global technical strategy for malaria 2016-2030, 2021 update. Jul 2021 [internet publication].Full text
15. World Health Organization. Global malaria programme. Countries and territories certified malaria-free by WHO. Oct 2024 [internet publication].Full text
16. Luxemburger C, Ricci F, Nosten F, et al. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):256-62. Abstract
17. Das JK, Lakhani S, Rahman AR, et al. Malaria in pregnancy: meta-analyses of prevalence and associated complications. Epidemiol Infect. 2024 Feb 13;152:e39.Full text Abstract
18. Wellems TE, Miller LH. Two worlds of malaria. N Engl J Med. 2003 Oct 16;349(16):1496-8. Abstract
19. Mungai M, Tegtmeier G, Chamberland M, et al. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001 Jun 28;344(26):1973-8.Full text Abstract
20. Centers for Disease Control and Prevention. Malaria outbreak: Bahia State, Brazil. Jan 2018 [internet publication].Full text
21. Whitty CJ, Edmonds S, Mutabingwa TK. Malaria in pregnancy. BJOG. 2005 Sep;112(9):1189-95. Abstract
22. Mendis K, Sina BJ, Marchesini P, et al. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 suppl):97-106. Abstract
23. Collins WE, Jeffery GM. Plasmodium ovale: parasite and disease. Clin Microbiol Rev. 2005 Jul;18(3):570-81.Full text Abstract
24. Boudin C, Robert V, Verhave JP, et al. Plasmodium falciparum and P. malariae epidemiology in a West African village. Bull World Health Organ. 1991;69(2):199-205.Full text Abstract
25. Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale - the "bashful" malaria parasites. Trends Parasitol. 2007 Jun;23(6):278-83. Abstract
26. Collins WE, Jeffery GM. Plasmodium malariae: parasite and disease. Clin Microbiol Rev. 2007 Oct;20(4):579-92.Full text Abstract
27. Anstey NM, Grigg MJ, Rajahram GS, et al. Knowlesi malaria: human risk factors, clinical spectrum, and pathophysiology. Adv Parasitol. 2021;113:1-43. Abstract
28. Brasil P, Zalis MG, de Pina-Costa A, et al. Outbreak of human malaria caused by Plasmodium simium in the Atlantic Forest in Rio de Janeiro: a molecular epidemiological investigation. Lancet Glob Health. 2017 Oct;5(10):e1038-46.Full text Abstract
29. Lalloo DG, Shingadia D, Bell DJ, et al. UK malaria treatment guidelines 2016. J Infect. 2016 Jun;72(6):635-49.Full text Abstract
30. Miller LH, Baruch DI, Marsh K, et al. The pathogenic basis of malaria. Nature. 2002 Feb 7;415(6872):673-9. Abstract
31. WWARN ACT Malaria and Malnutrition Study Group. Does acute malnutrition in young children increase the risk of treatment failure following artemisinin-based combination therapy? a WWARN individual patient data meta-analysis. Lancet Glob Health. 2024 Apr;12(4):e631-40.Full text Abstract
32. Smith AD, Bradley DJ, Smith V, et al. Imported malaria and high risk groups: observational study using UK surveillance data 1987-2006. BMJ. 2008 Jul 3;337:a120.Full text Abstract
33. Behrens RH, Carroll B, Smith V, et al. Declining incidence of malaria imported into the UK from West Africa. Malar J. 2008 Nov 10;7:235.Full text Abstract
34. Behrens RH, Carroll B, Beran J, et al; TropNetEurop. The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis? Malar J. 2007 Aug 23;6:114.Full text Abstract
35. Behrens RH, Bisoffi Z, Björkman A, et al; TropNetEurop. Malaria prophylaxis policy for travellers from Europe to the Indian sub-continent. Malar J. 2006 Feb 1;5:7.Full text Abstract
36. Krause G, Schöneberg I, Altmann D, et al. Chemoprophylaxis and malaria death rates. Emerg Infect Dis. 2006 Mar;12(3):447-51.Full text Abstract
37. Brabin BJ, Romagosa C, Abdelgalil S, et al. The sick placenta - the role of malaria. Placenta. 2004 May;25(5):359-78. Abstract
38. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000 Apr;94(suppl 1):S1-90. Abstract
39. Greenberg AE, Lobel HO. Mortality from plasmodium falciparum malaria in travelers from the United States, 1959 to 1987. Ann Intern Med. 1990 Aug 15;113(4):326-7. Abstract
40. Moore DA, Jennings RM, Doherty TF, et al. Assessing the severity of malaria. BMJ. 2003 Apr 12;326(7393):808-9.Full text Abstract
41. Hammerich A, Campbell OM, Chandramohan D. Unstable malaria transmission and maternal mortality - experiences from Rwanda. Trop Med Int Health. 2002 Jul;7(7):573-6.Full text Abstract
42. Moya-Alvarez V, Bodeau-Livinec F, Cot M. Iron and malaria: a dangerous liaison? Nutr Rev. 2016 Oct;74(10):612-23.Full text Abstract
43. Neuberger A, Okebe J, Yahav D, et al. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev. 2016 Feb 27;(2):CD006589.Full text Abstract
44. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - malaria. May 2023 [internet publication].Full text
45. Kolifarhood G, Raeisi A, Ranjbar M, et al. Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: a meta-analysis and systematic review. Travel Med Infect Dis. 2017 May-Jun;17:5-18. Abstract
46. Radeva-Petrova D, Kayentao K, ter Kuile FO, et al. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014;(10):CD000169.Full text Abstract
47. González R, Pons-Duran C, Piqueras M, et al. Mefloquine for preventing malaria in pregnant women. Cochrane Database Syst Rev. 2018 Nov 14;(11):CD011444.Full text Abstract
48. Käser AK, Arguin PM, Chiodini PL, et al. Imported malaria in pregnant women: a retrospective pooled analysis. Travel Med Infect Dis. 2015 Jul-Aug;13(4):300-10.Full text Abstract
49. World Health Organization. WHO guidelines for malaria. Oct 2023 [internet publication].Full text
50. World Health Organization. Malaria vaccine: WHO position paper - May 2024. May 2024 [internet publication].Full text
51. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015 Jul 4;386(9988):31-45.Full text Abstract
52. Björkman A, Benn CS, Aaby P, et al. RTS,S/AS01 malaria vaccine-proven safe and effective? Lancet Infect Dis. 2023 Aug;23(8):e318-22. Abstract
53. Chandramohan D, Zongo I, Sagara I, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021 Sep 9;385(11):1005-17.Full text Abstract
54. World Health Organization. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. Oct 2023 [internet publication].Full text
55. World Health Organization. WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease. Dec 2023 [internet publication].Full text
56. Datoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024 Feb 10;403(10426):533-44.Full text Abstract
57. Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017 May;17(5):498-509.Full text Abstract
58. Ishizuka AS, Lyke KE, DeZure A, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016 Jun;22(6):614-23.Full text Abstract
59. Datoo MS, Natama HM, Somé A, et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022 Sep 7 [epub ahead of print].Full text Abstract
60. Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria. Cochrane Database Syst Rev. 2018 Nov 6;(11):CD000363.Full text Abstract
61. Tiono AB, Ouédraogo A, Ouattara D, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. Lancet. 2018 Aug 18;392(10147):569-80. Abstract
62. Gleave K, Lissenden N, Chaplin M, et al. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev. 2021 May 24;(5):CD012776.Full text Abstract
63. Pryce J, Medley N, Choi L. Indoor residual spraying for preventing malaria in communities using insecticide-treated nets. Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD012688.Full text Abstract
64. Gabaldón Figueira JC, Wagah MG, Adipo LB, et al. Topical repellents for malaria prevention. Cochrane Database Syst Rev. 2023 Aug 21;8(8):CD015422.Full text Abstract
65. Fox T, Furnival-Adams J, Chaplin M, et al. House modifications for preventing malaria. Cochrane Database Syst Rev. 2022 Oct 6;10(10):CD013398.Full text Abstract
66. Walshe DP, Garner P, Adeel AA, et al. Larvivorous fish for preventing malaria transmission. Cochrane Database Syst Rev. 2017 Dec 11;(12):CD008090.Full text Abstract
67. Pryce J, Choi L, Richardson M, et al. Insecticide space spraying for preventing malaria transmission. Cochrane Database Syst Rev. 2018 Nov 2;(11):CD012689.Full text Abstract
68. Choi L, Majambere S, Wilson AL. Larviciding to prevent malaria transmission. Cochrane Database Syst Rev. 2019 Aug 14;(8):CD012736.Full text Abstract
69. Esu EB, Oringanje C, Meremikwu MM. Intermittent preventive treatment for malaria in infants. Cochrane Database Syst Rev. 2021 Jul 17;(7):CD011525.Full text Abstract
70. Thwing J, Williamson J, Cavros I, et al. Systematic review and meta-analysis of seasonal malaria chemoprevention. Am J Trop Med Hyg. 2024 Jan 3;110(1):20-31.Full text Abstract
71. Pons-Duran C, Wassenaar MJ, Yovo KE, et al. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database Syst Rev. 2024 Sep 26;9(9):CD006689.Full text Abstract
72. Shah MP, Hwang J, Choi L, et al. Mass drug administration for malaria. Cochrane Database Syst Rev. 2021 Sep 29;(9):CD008846.Full text Abstract
73. Cunnington AJ, Abbara A, Bawa FK, et al. Identification and management of co-infections in people with malaria. BMJ. 2024 Mar 13;384:e077512. Abstract
74. Payne D. Use and limitations of light microscopy for diagnosing malaria at the primary health care level. Bull World Health Organ. 1988;66(5):621-6.Full text Abstract
75. Pattanasin S, Proux S, Chompasuk D, et al. Evaluation of a new Plasmodium lactate dehydrogenase assay (OptiMAL-IT) for the detection of malaria. Trans R Soc Trop Med Hyg. 2003 Nov-Dec;97(6):672-4. Abstract
76. Ashley E, Touabi M, Ahrer M, et al. Evaluation of three parasite lactate dehydrogenase-based rapid diagnostic tests for the diagnosis of falciparum and vivax malaria. Malar J. 2009 Oct 27;8:241.Full text Abstract
77. Yerlikaya S, Campillo A, Gonzalez IJ. A systematic review: performance of rapid diagnostic tests for the detection of Plasmodium knowlesi, Plasmodium malariae, and Plasmodium ovale monoinfections in human blood. J Infect Dis. 2018 Jun 20;218(2):265-76.Full text Abstract
78. Stauffer WM, Cartwright CP, Olson DA, et al. Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practice. Clin Infect Dis. 2009 Sep 15;49(6):908-13.Full text Abstract
79. Nicastri E, Bevilacqua N, Sañé Schepisi M, et al. Accuracy of malaria diagnosis by microscopy, rapid diagnostic test, and PCR methods and evidence of antimalarial overprescription in non-severe febrile patients in two Tanzanian hospitals. Am J Trop Med Hyg. 2009 May;80(5):712-7.Full text Abstract
80. Odaga J, Sinclair D, Lokong JA, et al. Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings. Cochrane Database Syst Rev. 2014 Apr 17;(4):CD008998.Full text Abstract
81. Allen EN, Wiyeh AB, McCaul M. Adding rapid diagnostic tests to community-based programmes for treating malaria. Cochrane Database Syst Rev. 2022 Sep 8;(9):CD009527.Full text Abstract
82. World Health Organization. False-negative RDT results and implications of new reports of P. falciparum histidine-rich protein 2/3 gene deletions. Jul 2019 [internet publication].Full text
83. Gillet P, Scheirlinck A, Stokx J, et al. Prozone in malaria rapid diagnostics tests: how many cases are missed? Malar J. 2011 Jun 15;10:166.Full text Abstract
84. Li B, Sun Z, Li X, et al. Performance of pfHRP2 versus pLDH antigen rapid diagnostic tests for the detection of Plasmodium falciparum: a systematic review and meta-analysis. Arch Med Sci. 2017 Apr 1;13(3):541-9.Full text Abstract
85. Das S, Peck RB, Barney R, et al. Performance of an ultra-sensitive Plasmodium falciparum HRP2-based rapid diagnostic test with recombinant HRP2, culture parasites, and archived whole blood samples. Malar J. 2018 Mar 17;17(1):118.Full text Abstract
86. Hanscheid T. Diagnosis of malaria: a review of alternatives to conventional microscopy. Clin Lab Haematol. 1999 Aug;21(4):235-45. Abstract
87. Oliveira DA, Holloway BP, Durigon EL, et al. Polymerase chain reaction and a liquid-phase, nonisotopic hybridization for species-specific and sensitive detection of malaria infection. Am J Trop Med Hyg. 1995 Feb;52(2):139-44. Abstract
88. Heinemann M, Phillips RO, Vinnemeier CD, et al. High prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018. Malar J. 2020 Oct 12;19(1):366.Full text Abstract
89. Polley SD, González IJ, Mohamed D, et al. Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. J Infect Dis. 2013 Aug 15;208(4):637-44.Full text Abstract
90. Hopkins H, González IJ, Polley SD, et al. Highly sensitive detection of malaria parasitemia in a malaria-endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. J Infect Dis. 2013 Aug 15;208(4):645-52.Full text Abstract
91. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. Abstract
92. Arendt K, Demaerschalk BM, Wingerchuk DM, et al. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20. Abstract
93. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204. Abstract
94. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.Full text Abstract
95. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.Full text Abstract
96. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.Full text Abstract
97. Hanson J, Hossain A, Charunwatthana P, et al. Hyponatremia in severe malaria: evidence for an appropriate anti-diuretic hormone response to hypovolemia. Am J Trop Med Hyg. 2009 Jan;80(1):141-5.Full text Abstract
98. Centers for Disease Control and Prevention. Clinical overview of oropouche virus disease. Oct 2024 [internet publication].Full text
99. Morrison A, White JL, Hughes HR, et al. Oropouche virus disease among U.S. travelers - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Sep 5;73(35):769-73.Full text Abstract
100. Auwaerter PG. Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control? Expert Rev Anti Infect Ther. 2006 Dec;4(6):1039-49. Abstract
101. Centers for Disease Control and Prevention. Clinical features of malaria. Mar 2024 [internet publication].Full text
102. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 11: newly arrived immigrants, refugees & other migrants. May 2023 [internet publication].Full text
103. Centers for Disease Control and Prevention. Clinical testing and diagnosis for malaria. Mar 2024 [internet publication].Full text
104. British Society For Haematology. Guidelines for the laboratory diagnosis of malaria. Mar 2022 [internet publication].Full text
105. Centers for Disease Control and Prevention. Clinical guidance: malaria diagnosis & treatment in the U.S. Jun 2024 [internet publication].Full text
106. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004 Jan 3;363(9402):9-17. Abstract
107. World Health Organization. Malaria: withdrawal of oral artemisinin-based monotherapies. Oct 2017 [internet publication].Full text
108. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996 Jun 15;347(9016):1654-8. Abstract
109. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007483.Full text Abstract
110. Hatz C, Soto J, Nothdurft HD, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg. 2008 Feb;78(2):241-7.Full text Abstract
111. Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011 May;17(5):771-7.Full text Abstract
112. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012 Mar 31;11:102.Full text Abstract
113. Rolling T, Schmiedel S, Wichmann D, et al. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J. 2012 May 17;11:169.Full text Abstract
114. Askling HH, Bruneel F, Burchard G, et al. Management of imported malaria in Europe. Malar J. 2012 Sep 17;11:328.Full text Abstract
115. D'Acremont V, Landry P, Mueller I, et al. Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever. Am J Trop Med Hyg. 2002 May;66(5):481-6.Full text Abstract
116. Melzer M, Lacey S, Rait G. The case for outpatient treatment of Plasmodium falciparum malaria in a selected UK immigrant population. J Infect. 2009 Oct;59(4):259-63. Abstract
117. Toovey S. Effectiveness of co-artemether in an unsupervised outpatient setting for the treatment of falciparum malaria. Travel Med Infect Dis. 2008 Jan-Mar;6(1-2):29-31. Abstract
118. Briand V, Bouchaud O, Tourret J, et al. Hospitalization criteria in imported falciparum malaria. J Travel Med. 2007 Sep-Oct;14(5):306-11.Full text Abstract
119. US Food and Drug Administration. Mefloquine hydrochloride: drug safety communication - FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. Jul 2013 [internet publication].Full text
120. Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014 Jan 20;(1):CD010927.Full text Abstract
121. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016 Mar;16(3):357-65.Full text Abstract
122. Rosenthal PJ, Asua V, Bailey JA, et al. The emergence of artemisinin partial resistance in Africa: how do we respond? Lancet Infect Dis. 2024 Sep;24(9):e591-600.Full text Abstract
123. Chan XHS, Win YN, Mawer LJ, et al. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018 Aug;18(8):913-23.Full text Abstract
124. Sondén K, Wyss K, Jovel I, et al. High rate of treatment failures in nonimmune travelers treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Sweden: retrospective comparative analysis of effectiveness and case series. Clin Infect Dis. 2017 Jan 15;64(2):199-206.Full text Abstract
125. van Schalkwyk DA, Pratt S, Nolder D, et al. Treatment failure in a UK malaria patient harboring genetically variant Plasmodium falciparum from Uganda with reduced in vitro susceptibility to artemisinin and lumefantrine. Clin Infect Dis. 2024 Feb 17;78(2):445-52.Full text Abstract
126. Pryce J, Taylor M, Fox T, et al. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2022 Jun 21;(6):CD006404.Full text Abstract
127. Blanshard A, Hine P. Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2021 Jan 15;(1):CD004529.Full text Abstract
128. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014 Nov 3;13:418.Full text Abstract
129. Graves PM, Choi L, Gelband H, et al. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2018 Feb 2;(2):CD008152.Full text Abstract
130. Centers for Disease Control and Prevention. Appendix C: how to acquire IV artesunate in the United States. Mar 2024 [internet publication].Full text
131. World Health Organization. The use of rectal artesunate as a pre-referral treatment for severe P. falciparum malaria. Jul 2023 [internet publication].Full text
132. Esu EB, Effa EE, Opie ON, et al. Artemether for severe malaria. Cochrane Database Syst Rev. 2019 Jun 18;(6):CD010678.Full text Abstract
133. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis. 2008 Jan 15;46(2):165-71.Full text Abstract
134. Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated plasmodium falciparum and P vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003 Apr;68(4):416-20.Full text Abstract
135. John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012 Aug 17;11:280.Full text Abstract
136. Milligan R, Daher A, Villanueva G, et al. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. Cochrane Database Syst Rev. 2020 Aug 19;(8):CD012656.Full text Abstract
137. Taylor WRJ, Thriemer K, von Seidlein L, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019 Sep 14;394(10202):929-38.Full text Abstract
138. World Health Organization. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale. Oct 2016 [internet publication].Full text
139. Thriemer K, Degaga TS, Christian M, et al. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. Lancet. 2023 Dec 02;402(10417):2101-10.Full text
140. Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006 Sep;75(3):402-15.Full text Abstract
141. Rogerson SJ, Hviid L, Duffy PE,et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis. 2007 Feb;7(2):105-17. Abstract
142. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007 Feb;7(2):93-104. Abstract
143. Moore KA, Simpson JA, Scoullar MJL, et al. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. Lancet Glob Health. 2017 Nov;5(11):e1101-12.Full text Abstract
144. Cates JE, Unger HW, Briand V, et al. Malaria, malnutrition, and birthweight: a meta-analysis using individual participant data. PLoS Med. 2017 Aug 8;14(8):e1002373.Full text Abstract
145. Newman RD, Parise ME, Slutsker L, et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health. 2003 Jun;8(6):488-506.Full text Abstract
146. World Health Organization. Safety of artemisinin and non-artemisinin antimalarials in the first trimester of pregnancy. Apr 2024 [internet publication].Full text
147. Kovacs SD, van Eijk AM, Sevene E, et al. The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: a systematic review and meta-analysis. PLoS One. 2016 Nov 8;11(11):e0164963.Full text Abstract
148. Saito M, Mansoor R, Kennon K, et al. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2020 Aug;20(8):943-52.Full text Abstract
149. Dellicour S, Sevene E, McGready R, et al. First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLoS Med. 2017 May;14(5):e1002290.Full text Abstract
150. Osarfo J, Tagbor H, Cairns M, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial. Trop Med Int Health. 2017 Aug;22(8):1043-52.Full text Abstract
151. Pekyi D, Ampromfi AA, Tinto H, et al; PREGACT Study Group. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016 Mar 10;374(10):913-27.Full text Abstract
152. Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016 Mar 10;374(10):928-39.Full text Abstract
153. Desai M, Gutman J, L'Ianziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015 Dec 19;386(10012):2507-19.Full text Abstract
154. Burger RJ, van Eijk AM, Bussink M, et al. Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2015 Nov 12;3(1):ofv170.Full text Abstract
155. Mavoko HM, Nabasumba C, da Luz RI, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Glob Health. 2017 Jan;5(1):e60-8.Full text Abstract
156. World Health Organization. Status report on artemisinin resistance and artemisinin-based combination therapy efficacy. Dec 2019 [internet publication].Full text
157. Maitland K, Kiguli S, Opoka RO, et al; FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011 Jun 30;364(26):2483-95.Full text Abstract
158. Commons RJ, Simpson JA, Thriemer K, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1025-34.Full text Abstract
159. Rodrigo C, Rajapakse S, Fernando D. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2020 Sep 6;(9):CD010458.Full text Abstract
160. Sutanto I, Soebandrio A, Ekawati LL, et al. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis. 23 May 2023 [Epub ahead of print].Full text Abstract
161. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014 Mar 22;383(9922):1049-58. Abstract
162. Haston JC, Hwang J, Tan KR. Guidance for using tafenoquine for prevention and antirelapse therapy for malaria - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1062-8.Full text Abstract
163. Nguyen TD, Gao B, Amaratunga C, et al. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat Commun. 2023 Jul 29;14(1):4568.Full text Abstract
164. de Souza DK, Thomas R, Bradley J, et al. Ivermectin treatment in humans for reducing malaria transmission. Cochrane Database Syst Rev. 2021 Jun 29;(6):CD013117.Full text Abstract
165. Plewes K, Kingston HWF, Ghose A, et al. Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe falciparum malaria: a randomized, controlled, open-label trial. Clin Infect Dis. 2018 Sep 14;67(7):991-9.Full text Abstract
166. Cooper DJ, Grigg MJ, Plewes K, et al. The effect of regularly dosed acetaminophen versus no acetaminophen on renal function in Plasmodium knowlesi malaria (PACKNOW): a randomised controlled trial. Clin Infect Dis. 2022 Feb 18:ciac152.Full text Abstract
167. Wu RL, Idris AH, Berkowitz NM, et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N Engl J Med. 2022 Aug 4;387(5):397-407.Full text Abstract
168. Kayentao K, Ongoiba A, Preston AC, et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N Engl J Med. 2024 May 2;390(17):1549-59.Full text Abstract
169. van der Plas JL, Kuiper VP, Bagchus WM, et al. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. Lancet Infect Dis. 2023 Oct;23(10):1164-74. Abstract
170. Winters RA, Murray HW. Malaria - the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med. 1992 Sep;93(3):243-6. Abstract
171. Behrens RH, Curtis CF. Malaria in travellers: epidemiology and prevention. Br Med Bull. 1993 Apr;49(2):363-81. Abstract
172. White NJ. Not much progress in the treatment of cerebral malaria. Lancet. 1998 Aug 22;352(9128):594-5. Abstract
173. Bruneel F, Tubach F, Corne P, et al. Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS One. 2010 Oct 8;5(10):e13236.Full text Abstract
174. Checkley AM, Smith A, Smith V, et al. Risk factors for mortality from imported falciparum malaria in the United Kingdom over 20 years: an observational study. BMJ. 2012 Mar 27;344:e2116.Full text Abstract
175. Sypniewska P, Duda JF, Locatelli I, et al. Clinical and laboratory predictors of death in African children with features of severe malaria: a systematic review and meta-analysis. BMC Med. 2017 Aug 3;15(1):147.Full text Abstract
176. English M, Waruiru C, Amukoye E, et al. Deep breathing in children with severe malaria: indicador of metabolic acidosis and poor outcome. Am J Trop Med Hyg. 1996 Nov;55(5):521-4. Abstract
177. Lon C, Spring M, Sok S, et al. Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine. Malar J. 2014 Mar 14;13:96.Full text Abstract
178. Yadava SK, Laleker A, Fazili T. Post-malaria neurological syndrome: a rare neurological complication of malaria. Infection. 2019 Apr;47(2):183-93.Full text Abstract
Use of this content is subject to our disclaimer